Rezultati pretraživanja
  1. 15. kol 2014.

    I'm supporting 's fight to make available pre-chemotherapy on the NHS. Join me & sign up now

  2. 31. svi 2019.

    Alliance A031201: + not better than alone

  3. Received this inspired poem from one of my patients, really made me smile

  4. 14. velj 2019.

    metastasis-directed therapy, represents a viable and cost-effective therapy for compared to upfront systemics + ADT or alone

  5. 16. stu 2017.

    Excellent presentations Now Discussion in hormone naive#prostatecancer session or we don't now which is better

  6. 13. sij

    Great news that has been approved in Scotland as a first-line treatment for men with advanced prostate . This drug will now benefit many more men with the disease than before!

  7. 14. stu 2019.

    To the hundreds of you who worked on COU-302: a reminder that this study changed SOC worldwide and has now been cited >1000 X . honored this on a#wallofscholarship. Congratulations! Let’s do it again! EricSmall

    Prikaži ovu nit
  8. Article Online: Optimal of and acetate plus in metastatic castration-resistant : a randomised, open-label, phase 2 crossover trial

    Prikaži ovu nit
  9. 7. pro 2017.

    Bayer has been forced to unblind a trial looking at the combination of radium 223 (Xofiga) and (Zytiga) after an excess of deaths and fractures were noted in the combination group compared to the abiraterone group alone -

  10. 31. svi 2019.

    Dr. Kim Chi phase II of cabazitaxel (CAB) vs or in poor-risk showed improved CBR with CAB and prolonged SD, trend to OS benefit with first-line CAB

  11. 25. ožu 2019.

    Fascinating feature on 🧬 in by - the piece focuses on research but also touches on 's work (and the ICR-discovered drug / ).

  12. 8. velj 2018.
  13. A standard dose of prednisone of 5 mg/day as recommended previously may be inadequate to achieve physiologic glucocorticoid replacement in some patients with while on treatment. Additionally 10 mg of prednisone may cause adverse effects (continues)

    Prikaži ovu nit
  14. 14. velj 2019.

    Three positive studies discussed in detail by of M0 NmCRPC over PBO M1 HSPC over PBO + over PBO

    Ovo je potencijalno osjetljiv multimedijski sadržaj. Saznajte više
  15. 31. svi 2019.

    Dr. Morris: simply not that much more anticancer activity w/addition of to vs enza alone in phase III trial in . More AEs with combination

  16. 4. stu 2017.

    Dr Mukherji reviews data in advanced castration-sensitive @apccc17 How select patients?

  17. 4. lip 2017.

    In head to head comparison w better PSA resp cw but no difference in PFS in

  18. 1. pro 2017.

    is one of the ICR’s biggest success stories. Read its story of scientific innovation and commercial partnership

  19. Big day today, our 20th Cork patient has been registered onto the Neoadjuvant Abiraterone Prostate Study- Well done team!

  20. 6. tra 2018.

    “Patients with DRD had significantly...longer median PFS vs those with wild-type tumors...The mutual exclusivity between DRD and PTEN could further explain why patients with WT DNA repair had worse outcome with therapy.”

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.